Cephalon to pay $425M for improper marketing

September 29, 2008 8:21:47 AM PDT
Federal authorities have announced a $425 million civil settlement with a pharmaceutical company charged with off-label drug marketing. Authorities in Philadelphia say Cephalon marketed three drugs for uses other than what they were federally approved for.

Authorities say Cephalon marketed one of the drugs, Actiq, for maladies including migraines and injuries. But authorities say the fentanyl lollipop is a highly addictive narcotic only approved for certain cancer patients.

The suburban Philadelphia company has signed an agreement to plead guilty to one count of distribution of misbranded drugs.

Click here to get the latest Philadelphia news and headlines from across the Delaware and Lehigh valleys.


Load Comments